Eculizumab treatment in patients with COVID-19 : preliminary results from real life ASL Napoli 2 Nord experience
OBJECTIVE: SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2)-related pneumonia, referred to as COVID-19 (Coronavirus Disease 19), is a public health emergency as it carries high morbidity, mortality, and has no approved specific pharmacological treatments. In this case series, we aimed to report preliminary data obtained with anti-complement C5 therapy with eculizumab in COVID-19 patients admitted to intensive care unit (ICU) of ASL Napoli 2 Nord.
PATIENTS AND METHODS: This is a case series of patients with a confirmed diagnosis of SARS-CoV2 infection and severe pneumonia or ARDS who were treated with up to 4 infusions of eculizumab as an off-label agent. Patients were also treated with anticoagulant therapy with Enoxaparin 4000 IU/day via subcutaneous injection, antiviral therapy with Lopinavir 800 mg/day + Ritonavir 200 mg/day, hydroxychloroquine 400 mg/day, ceftriaxone 2 g/day IV, vitamine C 6 g/day for 4 days, and were on Non-Invasive Ventilation (NIV).
RESULTS: We treated four COVID-19 patients admitted to the intensive care unit because of severe pneumonia or ARDS. All patients successfully recovered after treatment with eculizumab. Eculizumab induced a drop in inflammatory markers. Mean C Reactive Protein levels dropped from 14.6 mg/dl to 3.5 mg/dl and the mean duration of the disease was 12.8 days.
CONCLUSIONS: Eculizumab has the potential to be a key player in treatment of severe cases of COVID-19. Our results support eculizumab use as an off-label treatment of COVID-19, pending confirmation from the ongoing SOLID-C19 trial.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
European review for medical and pharmacological sciences - 24(2020), 7 vom: 20. Apr., Seite 4040-4047 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Diurno, F [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
A3ULP0F556 |
|---|
| Anmerkungen: |
Date Completed 29.04.2020 Date Revised 18.12.2020 published: Print CommentOn: mBio. 2018 Oct 9;9(5):. - PMID 30301856 Citation Status MEDLINE |
|---|
| doi: |
10.26355/eurrev_202004_20875 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM30914213X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM30914213X | ||
| 003 | DE-627 | ||
| 005 | 20231225133247.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.26355/eurrev_202004_20875 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1030.xml |
| 035 | |a (DE-627)NLM30914213X | ||
| 035 | |a (NLM)32329881 | ||
| 035 | |a (PII)20875 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Diurno, F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Eculizumab treatment in patients with COVID-19 |b preliminary results from real life ASL Napoli 2 Nord experience |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.04.2020 | ||
| 500 | |a Date Revised 18.12.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: mBio. 2018 Oct 9;9(5):. - PMID 30301856 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2)-related pneumonia, referred to as COVID-19 (Coronavirus Disease 19), is a public health emergency as it carries high morbidity, mortality, and has no approved specific pharmacological treatments. In this case series, we aimed to report preliminary data obtained with anti-complement C5 therapy with eculizumab in COVID-19 patients admitted to intensive care unit (ICU) of ASL Napoli 2 Nord | ||
| 520 | |a PATIENTS AND METHODS: This is a case series of patients with a confirmed diagnosis of SARS-CoV2 infection and severe pneumonia or ARDS who were treated with up to 4 infusions of eculizumab as an off-label agent. Patients were also treated with anticoagulant therapy with Enoxaparin 4000 IU/day via subcutaneous injection, antiviral therapy with Lopinavir 800 mg/day + Ritonavir 200 mg/day, hydroxychloroquine 400 mg/day, ceftriaxone 2 g/day IV, vitamine C 6 g/day for 4 days, and were on Non-Invasive Ventilation (NIV) | ||
| 520 | |a RESULTS: We treated four COVID-19 patients admitted to the intensive care unit because of severe pneumonia or ARDS. All patients successfully recovered after treatment with eculizumab. Eculizumab induced a drop in inflammatory markers. Mean C Reactive Protein levels dropped from 14.6 mg/dl to 3.5 mg/dl and the mean duration of the disease was 12.8 days | ||
| 520 | |a CONCLUSIONS: Eculizumab has the potential to be a key player in treatment of severe cases of COVID-19. Our results support eculizumab use as an off-label treatment of COVID-19, pending confirmation from the ongoing SOLID-C19 trial | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a eculizumab |2 NLM | |
| 650 | 7 | |a A3ULP0F556 |2 NLM | |
| 700 | 1 | |a Numis, F G |e verfasserin |4 aut | |
| 700 | 1 | |a Porta, G |e verfasserin |4 aut | |
| 700 | 1 | |a Cirillo, F |e verfasserin |4 aut | |
| 700 | 1 | |a Maddaluno, S |e verfasserin |4 aut | |
| 700 | 1 | |a Ragozzino, A |e verfasserin |4 aut | |
| 700 | 1 | |a De Negri, P |e verfasserin |4 aut | |
| 700 | 1 | |a Di Gennaro, C |e verfasserin |4 aut | |
| 700 | 1 | |a Pagano, A |e verfasserin |4 aut | |
| 700 | 1 | |a Allegorico, E |e verfasserin |4 aut | |
| 700 | 1 | |a Bressy, L |e verfasserin |4 aut | |
| 700 | 1 | |a Bosso, G |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrara, A |e verfasserin |4 aut | |
| 700 | 1 | |a Serra, C |e verfasserin |4 aut | |
| 700 | 1 | |a Montisci, A |e verfasserin |4 aut | |
| 700 | 1 | |a D'Amico, M |e verfasserin |4 aut | |
| 700 | 1 | |a Schiano Lo Morello, S |e verfasserin |4 aut | |
| 700 | 1 | |a Di Costanzo, G |e verfasserin |4 aut | |
| 700 | 1 | |a Tucci, A G |e verfasserin |4 aut | |
| 700 | 1 | |a Marchetti, P |e verfasserin |4 aut | |
| 700 | 1 | |a Di Vincenzo, U |e verfasserin |4 aut | |
| 700 | 1 | |a Sorrentino, I |e verfasserin |4 aut | |
| 700 | 1 | |a Casciotta, A |e verfasserin |4 aut | |
| 700 | 1 | |a Fusco, M |e verfasserin |4 aut | |
| 700 | 1 | |a Buonerba, C |e verfasserin |4 aut | |
| 700 | 1 | |a Berretta, M |e verfasserin |4 aut | |
| 700 | 1 | |a Ceccarelli, M |e verfasserin |4 aut | |
| 700 | 1 | |a Nunnari, G |e verfasserin |4 aut | |
| 700 | 1 | |a Diessa, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Cicala, S |e verfasserin |4 aut | |
| 700 | 1 | |a Facchini, G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European review for medical and pharmacological sciences |d 1997 |g 24(2020), 7 vom: 20. Apr., Seite 4040-4047 |w (DE-627)NLM09387944X |x 2284-0729 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2020 |g number:7 |g day:20 |g month:04 |g pages:4040-4047 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.26355/eurrev_202004_20875 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2020 |e 7 |b 20 |c 04 |h 4040-4047 | ||